Data from this analysis show that S100A9 is more sensitive in NASH than in T2DM, which strongly suggests that S100A9 may be an ideal biomarker for hepatic progression in NAFLD but not for metabolic disorders. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatohepatitis.